Saturday, January 7, 2012

The Drexel Crowd Strikes Again (Yay, Drexel!)

The Journal of Pain
Volume 13, Issue 1 , Pages 10-20, January 2012



Changes in Plasma Cytokines and Their Soluble Receptors in Complex Regional Pain Syndrome

Guillermo M. Alexander, B. Lee Peterlin, Marielle J. Perreault, John R. Grothusen, Robert J. Schwartzman (All from the Dept of Neurology at Drexel, except for Peterlin from the Dept of Neurology at Hopkins)

Abstract
Complex Regional Pain Syndrome (CRPS) is a chronic and often disabling pain disorder. There is evidence demonstrating that neurogenic inflammation and activation of the immune system play a significant role in the pathophysiology of CRPS. This study evaluated the plasma levels of cytokines, chemokines, and their soluble receptors in 148 subjects afflicted with CRPS and in 60 gender- and age-matched healthy controls. Significant changes in plasma cytokines, chemokines, and their soluble receptors were found in subjects with CRPS as compared with healthy controls. For most analytes, these changes resulted from a distinct subset of the CRPS subjects. When the plasma data from the CRPS subjects was subjected to cluster analysis, it revealed 2 clusters within the CRPS population. The category identified as most important for cluster separation by the clustering algorithm was TNFα. Cluster 1 consisted of 64% of CRPS subjects and demonstrated analyte values similar to the healthy control individuals. Cluster 2 consisted of 36% of the CRPS subjects and demonstrated significantly elevated levels of most analytes and in addition, it showed that the increased plasma analyte levels in this cluster were correlated with disease duration and severity.

Perspective
The identification of biomarkers that define disease subgroups can be of great value in the design of specific therapies and of great benefit to the design of clinical trials. It may also aid in advancing our understanding of the mechanisms involved in the pathophysiology of CRPS, which may lead to novel treatments for this very severe condition.



References 

  1. Abbadie C. Chemokines, chemokine receptors and pain. Trends Immunol. 2005;26:529–534
  2. Alexander GM, van Rijn MA, van Hilten JJ, Perreault MJ, Schwartzman RJ. Changes in cerebrospinal fluid levels of proinflammatory cytokines in CRPS. Pain. 2005;116:213–219
  3. Alexander GM, Perreault MJ, Reichenberger ER, Schwartzman RJ. Changes in immune and glial markers in the CSF of patients with Complex Regional Pain Syndrome. Brain Behav Immun. 2007;21:668–676
  4. Bernateck M, Rolke R, Birklein F, Treede RD, Fink M, Karst M. Successful intravenous regional block with low-dose tumor necrosis factor-alpha antibody infliximab for treatment of complex regional pain syndrome 1. Anesth Analg.2007;105:1148–1151
  5. Birklein F, Schmelz M, Schifter S, Weber M. The important role for neuropeptides in complex regional pain syndrome.Neurology. 2001;57:2179–2184
  6. Bruehl S, Harden RN, Galer BS, Saltz S, Bertram M, Backonja M, et al. External validation of IASP diagnostic criteria for Complex Regional Pain Syndrome and proposed research diagnostic criteria. International Association for the Study of Pain. Pain.1999;81:147–154
  7. Bruehl S, Harden RN, Galer BS, Saltz S, Backonja M, Stanton-Hicks M. Complex regional pain syndrome: Are there distinct subtypes and sequential stages of the syndrome?. Pain. 2002;95:119–124
  8. Cattell RB. The scree test for the number of factors. Multivariate Behav Res. 1966;1:245–276
    • Costigan M, Scholz J, Woolf CJ. Neuropathic pain: A maladaptive response of the nervous system to damage. Annu Rev Neurosci. 2009;32:1–32
    • DeLeo JA, Yezierski RP. The role of neuroinflammation and neuroimmune activation in persistent pain. Pain. 2001;90:1–6
    • Goldberg ME, Domsky R, Scaringe D, Hirsh R, Dotson J, Sharaf I, et al. Multi-day low dose ketamine infusion for the treatment of complex regional pain syndrome. Pain Physician. 2005;8:175–179
    • Harden RN, Bruehl S, Perez RS, Birklein F, Marinus J, Maihofner C, et al. Validation of proposed diagnostic criteria (the "Budapest Criteria") for Complex Regional Pain Syndrome. Pain. 2010;150:268–274
    • Heijmans-Antonissen C, Wesseldijk F, Munnikes RJ, Huygen FJ, van der Meijden P, Hop WC, et al. Multiplex bead array assay for detection of 25 soluble cytokines in blister fluid of patients with complex regional pain syndrome type 1. Mediators Inflamm. 2006;2006:1–8
    • Heldestad V, Linder J, Sellersjö L, Nordh E. Reproducibility and influence of test modality order on thermal perception and thermal pain thresholds in quantitative sensory testing. Clin Neurophysiol. 2010;121:1878–1885
    • Huygen FJ, De Bruijn AG, De Bruin MT, Groeneweg JG, Klein J, Zijlstra FJ. Evidence for local inflammation in complex regional pain syndrome type 1. Mediators Inflamm. 2002;11:47–51
    • Huygen FJ, Niehof S, Zijlstra FJ, van Hagen PM, van Daele PL. Successful treatment of CRPS 1 with anti-TNF. J Pain Symptom Manage. 2004;27:101–103
    • Huygen FJ, Ramdhani N, van Toorenenbergen A, Klein J, Zijlstra FJ. Mast cells are involved in inflammatory reactions during Complex Regional Pain Syndrome type 1. Immunol Lett. 2004;91:147–154
    • Janig W, Baron R. Complex regional pain syndrome: Mystery explained?. Lancet Neurol. 2003;2:687–697
    • Kaiser HF. The application of electronic computers to factor analysis. Educ Psychol Meas. 1960;20:141–151
      • Krämer HH, Eberle T, Üçeyler N, Wagner I, Klonschinsky T, Müller LP, et al. TNF-alpha in CRPS and ‘normal’ trauma – Significant differences between tissue and serum. Pain. 2011;152:285–290
      • Maihöfner C, Handwerker HO, Neundörfer B, Birklein F. Mechanical hyperalgesia in complex regional pain syndrome: A role for TNF-alpha?. Neurology. 2005;65:311–313
      • Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. Nat Rev Neurosci. 2005;6:521–532
        • McMahon SB, Cafferty WB, Marchand F. Immune and glial cell factors as pain mediators and modulators. Exp Neurol.2005;192:444–462
        • Munnikes RJ, Muis C, Boersma M, Heijmans-Antonissen C, Zijlstra FJ, Huygen FJ. Intermediate stage complex regional pain syndrome type 1 is unrelated to proinflammatory cytokines. Mediators Inflamm. 2005;2005:366–372
        • Munts AG, Zijlstra FJ, Nibbering PH, Daha MR, Marinus J, Dahan A, et al. Analysis of cerebrospinal fluid inflammatory mediators in chronic complex regional pain syndrome related dystonia. Clin J Pain. 2008;24:30–34
        • Oaklander AL, Fields HL. Is reflex sympathetic dystrophy/complex regional pain syndrome type I a small-fiber neuropathy?. Ann Neurol. 2009;65:629–638
        • Schinkel C, Gaertner A, Zaspel J. Inflammatory mediators are altered in the acute phase of posttraumatic complex regional pain syndrome. Clin J Pain. 2006;22:235–239
        • Schinkel C, Scherens A, Köller M, Roellecke G, Muhr G, Maier C. Systemic inflammatory mediators in post-traumatic complex regional pain syndrome (CRPS I) - longitudinal investigations and differences to control groups. Eur J Med Res.2009;14:130–135
          • Schwartzman RJ, Grothusen J, Kiefer TR, Rohr P. Neuropathic central pain: Epidemiology, etiology, and treatment options.Arch Neurol. 2001;58:1547–1550
          • Schwartzman RJ, Chevlen E, Bengtson K. Thalidomide has activity in treating complex regional pain syndrome. Arch Intern Med. 2003;163:1487–1488
          • Schwartzman RJ, Alexander GM, Grothusen J. The pathophysiology of complex regional pain syndrome. Expert Rev Neurother.2006;6:669–681
          • Schwartzman RJ, Erwin KL, Alexander GM. The natural history of complex regional pain syndrome. Clin J Pain. 2009;25:273–280
          • Schwartzman RJ, Alexander GM, Grothusen JR, Paylor T, Reichenberger E, Perreault M. Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: A double-blind placebo controlled study. Pain. 2009;147:107–115
          • Schwartzman RJ, Patel M, Grothusen JR, Alexander GM. Efficacy of 5-day continuous lidocaine infusion for the treatment of refractory complex regional pain syndrome. Pain Med. 2009;10:401–412
          • Sommer C, Kress M. Recent findings on how proinflammatory cytokines cause pain: Peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett. 2004;361:184–187
          • Stanton-Hicks M, Jänig W, Hassenbusch S, Haddox JD, Boas R, Wilson P. Reflex sympathetic dystrophy: Changing concepts and taxonomy. Pain. 1995;63:127–133
          • Uçeyler N, Eberle T, Rolke R, Birklein F, Sommer C. Differential expression patterns of cytokines in complex regional pain syndrome. Pain. 2007;132:195–205
          • van de Beek WJ, Remarque EJ, Westendorp RG, van Hilten JJ. Innate cytokine profile in patients with complex regional pain syndrome is normal. Pain. 2001;91:259–261
          • Wasner GL, Brock JA. Determinants of thermal pain thresholds in normal subjects. Clin Neurophysiol. 2008;119:2389–2395
          • Watkins LR, Maier SF. Glia: A novel drug discovery target for clinical pain. Nat Rev Drug Discov. 2003;2:973–985
          • Watkins LR, Maier SF. Immune regulation of central nervous system functions: From sickness responses to pathological pain. J Intern Med. 2005;257:139–155
          • Waxman SG, Dib-Hajj S, Cummins TR, Black JA. Sodium channels and pain. Proc Natl Acad Sci U S A. 1999;96:7635–7639
          • White paper – technical report. The SPSS TwoStep Cluster Component.http://www.spss.ch/upload/1122644952_The%20SPSS%20TwoStep%20Cluster%20Component.pdf. Accessed November 30, 2011
            • Woolf CJ, Salter MW. Neuronal plasticity: Increasing the gain in pain. Science. 2000;288:1765–1769
            • Yarnitsky D, Sprecher E. Thermal testing: Normative data and repeatability for various test algorithms. J Neurol Sci.1994;125:39–45
            • Yarnitsky D, Sprecher E, Zaslansky R, Hemli JA. Heat pain thresholds: Normative data and repeatability. Pain. 1995;60:329–332
            • Zwingenberger K, Wnendt S. Immunomodulation by thalidomide: Systematic review of the literature and of unpublished observations. J Inflamm. 1995;46:177–211

            [less laudatory drexel associations...]
            at
            Labels: , , , , , ,

            No comments:

            Post a Comment

            The Haddock Corporation's newest dictate: Anonymous comments are no longer allowed. It is easy enough to register and just takes a moment. We look forward to hearing from you non-bots and non-spammers!

            Subscribe to: Post Comments (Atom)